临床消化病杂志
臨床消化病雜誌
림상소화병잡지
Chinese Journal of Clinical Gastroenterology
2015年
5期
295-297
,共3页
亚临床肝性脑病%门冬氨酸鸟氨酸%双歧杆菌三联活菌%疗效
亞臨床肝性腦病%門鼕氨痠鳥氨痠%雙歧桿菌三聯活菌%療效
아림상간성뇌병%문동안산조안산%쌍기간균삼련활균%료효
subclinical hepatic encephalopathy%L-ornithin-L-aspartate%bifid triple viable tablet%clinical effects
[目的]观察门冬氨酸鸟氨酸联合双歧杆菌三联活菌治疗亚临床肝性脑病（SHE）的疗效。[方法]56例SHE患者按就诊科室随机分为2组，对照组（24例）予常规护肝治疗，治疗组（32例）在对照组治疗的基础上加门冬氨酸鸟氨酸及双歧杆菌三联活菌口服，2组均给药8周。测定2组治疗前后血氨水平、智力测验[数字连接试验（NCT）、数字符号试验（DST）]结果，并观察肝性脑病发病率。[结果]治疗组与对照组血氨水平、NCT、DST均有改善，治疗组治疗后血氨水平下降、DST缩短、SHE发病率下降，与对照组相比差异有统计学意义（P＜0.05）。[结论]门冬氨酸鸟氨酸联合双歧杆菌三联活菌治疗可降低血氨水平，改善肠道菌群失调，降低肝性脑病的发病率。
[目的]觀察門鼕氨痠鳥氨痠聯閤雙歧桿菌三聯活菌治療亞臨床肝性腦病（SHE）的療效。[方法]56例SHE患者按就診科室隨機分為2組，對照組（24例）予常規護肝治療，治療組（32例）在對照組治療的基礎上加門鼕氨痠鳥氨痠及雙歧桿菌三聯活菌口服，2組均給藥8週。測定2組治療前後血氨水平、智力測驗[數字連接試驗（NCT）、數字符號試驗（DST）]結果，併觀察肝性腦病髮病率。[結果]治療組與對照組血氨水平、NCT、DST均有改善，治療組治療後血氨水平下降、DST縮短、SHE髮病率下降，與對照組相比差異有統計學意義（P＜0.05）。[結論]門鼕氨痠鳥氨痠聯閤雙歧桿菌三聯活菌治療可降低血氨水平，改善腸道菌群失調，降低肝性腦病的髮病率。
[목적]관찰문동안산조안산연합쌍기간균삼련활균치료아림상간성뇌병（SHE）적료효。[방법]56례SHE환자안취진과실수궤분위2조，대조조（24례）여상규호간치료，치료조（32례）재대조조치료적기출상가문동안산조안산급쌍기간균삼련활균구복，2조균급약8주。측정2조치료전후혈안수평、지력측험[수자련접시험（NCT）、수자부호시험（DST）]결과，병관찰간성뇌병발병솔。[결과]치료조여대조조혈안수평、NCT、DST균유개선，치료조치료후혈안수평하강、DST축단、SHE발병솔하강，여대조조상비차이유통계학의의（P＜0.05）。[결론]문동안산조안산연합쌍기간균삼련활균치료가강저혈안수평，개선장도균군실조，강저간성뇌병적발병솔。
Objective]To observe the clinical effects of L‐ornithin‐L‐aspartate and bifid triple viable tab‐let on the treatment of subclinical hepatic encephalopathy (SHE).[Methods]Fifty‐six SHE patients were randomly divided into 2 groups.Patiens in the control group(24 cases)were given general supportive for 8 weeks.Patiens in the trial group(32 cases)were given L‐ornithin‐L‐aspartate and bifid triple viable tablet plus general supportive for 8 weeks too.[Results] Blood ammonia ,NCT and DST were improved in both group.There were significant difference in blood ammonia and DST between the two group.The SHE inci‐dence in the trial group was significantly lower than that in the control group.[Conclusion]L‐ornithin‐L‐as‐partate and bifid triple viable tablet can decrease blood ammonia and decrease the incidence of SHE.
